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Background:Mitochondrial dysfunction is considered crucial for triggering NLRP3 inflammasome activation.
Results: Rotenone-induced impairment of mitochondrial electron transport chain promotes NLRP3 inflammasome activation
exclusively with ATP but not with other NLRP3-activating stimulators.
Conclusion: High-grade mROS and hyperpolarization are essential for NLRP3 inflammasome activation upon rotenone-
induced mitochondrial dysfunction.
Significance:Mitochondrial impairmentmay selectively primeNLRP3 inflammasome activation, leading tomany degenerative
diseases.
Mitochondrial dysfunction is considered crucial for NLRP3
inflammasome activation partly through its release of mito-
chondrial toxic products, such asmitochondrial reactive oxygen
species (mROS)2 and mitochondrial DNA (mtDNA). Although
previous studies have shown that classical NLRP3-activating
stimulations lead to mROS generation and mtDNA release, it
remains poorly understood whether and how mitochondrial
damage-derived factors may contribute to NLRP3 inflam-
masome activation. Here, we demonstrate that impairment of
the mitochondrial electron transport chain by rotenone primes
NLRP3 inflammasome activation only upon costimulation with
ATP andnotwith nigericin or alum. Rotenone-induced priming
of NLRP3 in the presence of ATP triggered the formation of
specklike NLRP3 or ASC aggregates and the association of
NLRP3 with ASC, resulting in NLRP3-dependent caspase-1
activation. Mechanistically, rotenone confers a priming signal
forNLRP3 inflammasome activation only in the context of aber-
rant high-grade, but not low-grade, mROS production and
mitochondrial hyperpolarization. By contrast, rotenone/ATP-
mediatedmtDNA release andmitochondrial depolarization are
likely to be merely an indication of mitochondrial damage
rather than triggering factors for NLRP3 inflammasome activa-
tion. Our results provide a molecular insight into the selective
contribution made by mitochondrial dysfunction to the NLRP3
inflammasome pathway.
The inflammasome is a multiprotein complex that is assem-
bled upon sensing of pathogen- or danger-associatedmolecular
patterns by a sensor molecule, such as nucleotide-binding olig-
omerization domain-like receptor family, pyrin domain-con-
taining 3 (NLRP3) (1). The assembled inflammasome complex
promotes theactivationofcaspase-1, leading to theprocessingand
release of interleukin-1 (IL-1) (2). Activation of inflammasome
signaling thus triggers the initial inflammatory responses at
infected or injured sites primarily by secreting IL-1; however,
deregulated or chronic inflammasome activation is potentially
implicated inmetabolic and neurodegenerative disorders, such as
type 2 diabetes and Alzheimer disease (3, 4).
Although NLRP3 is the best characterized inflammasome
sensor molecule, its detailed activation mechanism remains
poorly understood (5). Conventionally, the activation and
assembly of the NLRP3 inflammasome require two indepen-
dent signals: signal 1 for transcriptional induction of NLRP3
and pro-IL-1 and signal 2 for the activation of inflammasome
components (2). However, recent findings have revealed that
the post-transcriptionalmodification ofNLRP3 by either signal
1 or signal 2 is also crucial for NLRP3 inflammasome activation
(6–8). The way in which the NLRP3 inflammasome is assem-
bled and activated in response to a wide range of stimulations is
therefore now considered to be more complicated than previ-
ously believed. Much attention is now being paid to the poten-
tial role played by mitochondria in modulating NLRP3 inflam-
masome activation as a central common hub for diverse
agonists (9). Recent evidence has shown that NLRP3-activating
stimulations induce mitochondrial damage, resulting in the
release of mitochondrial reactive oxygen species (mROS) and
mitochondrial DNA (mtDNA), and it has been hypothesized
that thesemitochondria-derived toxic productsmay act as cru-
cial mediators in activating NLRP3 (10–13).
Mitochondrial dysfunction has been extensively studied in
terms of its connection to multiple degenerative disorders (14,
15). Considering that NLRP3 inflammasome signaling is also
potentially implicated in metabolic or neurodegenerative dis-
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orders, mitochondrial dysfunction may contribute to the
pathogenesis of degenerative diseases by activating the NLRP3
inflammasome.Mitochondrial dysfunctionmay be experimen-
tally induced by several chemicals, including rotenone (16).
Rotenone impairs mitochondrial respiration by inhibiting elec-
tron transport chain (ETC) complex I, leading to ATP deple-
tion, mROS production, and the loss of mitochondrial mem-
brane potential (16, 17). Interestingly, rotenone is also used to
induce Parkinson disease in experimental animal models, pos-
sibly through the malfunction of ETC complex I (18).
Previous studies have shown that the inhibition ofmitochon-
drial ETC complex by rotenone or antimycin A leads to NLRP3
inflammasome activation (10). By contrast, various studies have
demonstrated that rotenone fails to activate caspase-1 (19) or
even suppresses caspase-1 activation upon NLRP3-dependent
stimuli, such as ATP, nigericin, alum, or silica (13). Similarly, a
protonophore, carbonyl cyanide m-chlorophenylhydrazone
(CCCP), which induces the dissipation of mitochondrial mem-
brane potential andmitochondrial fission, was reported to pro-
mote or inhibit NLRP3 inflammasome activation (10, 20). In
this regard, the contribution made by mitochondrial impair-
ment to the NLRP3 pathway requires additional clarification in
order to provide amolecular insight into themechanismunder-
lying NLRP3 inflammasome activation. We therefore closely
examined howdirectmitochondrial dysfunction affectsNLRP3
inflammasome activation.
Experimental Procedures
Reagents and Antibodies—LPS, rotenone, CCCP, ATP, nige-
ricin, N-acetyl-L-cysteine (NAC), cyclosporin A, menadione,
and U0126 were purchased from Sigma-Aldrich. Alum was
obtained from InvivoGen. Z-VAD-fmk was obtained from
Bachem. Mito-SOX, MitoTracker Green, and MitoTracker
Deep Red were purchased from Invitrogen. Mito-TEMPO was
purchased fromSantaCruzBiotechnology, Inc. PR619was pur-
chased from LifeSensors. Anti-IL-1 antibody (AF-401-NA)
was obtained from R&D Systems. Anti-caspase-1 (AG-20B-
0042) and NLRP3 (AG-20B-0014) antibodies were purchased
from Adipogen. Anti-ASC (apoptosis-associated speck-like
protein containing a caspase recruitment domain) antibody
(SC-22514) was purchased from Santa Cruz Biotechnology.
Cell Culture—Mouse bone marrow-derived macrophages
(BMDMs) were prepared from C57BL/6 or Nlrp3-deficient
mice as described previously (21). All mice were maintained in
specific pathogen-free conditions. Protocols for mice experi-
ments were approved by the Institutional Ethical Committee of
the Yonsei University College of Medicine. Immortalized
wild-type, Asc-deficient, Nlrp3-deficient, NLRP3-reconsti-
tuted (N1–8), orNLRP3-GFP-expressingmouse BMDMswere
kindly provided byDr. E. S. Alnemri (Thomas JeffersonUniver-
sity, Philadelphia, PA). All of the BMDMs were grown in L929-
conditioned DMEM, which was supplemented with 10% FBS
and 100 units/ml penicillin-streptomycin.
Immunoblot Analysis—Cells were lysed in 20mMHEPES (pH
7.5) buffer containing 0.5% Nonidet P-40, 50 mM KCl, 150 mM
NaCl, 1.5 mM MgCl2, 1 mM EGTA, and protease inhibitors.
Soluble lysates underwent SDS-PAGE and were then immuno-
blottedwith the appropriate antibodies. For the coimmunopre-
cipitation experiment, cells were lysed in 10 mM HEPES buffer
(pH 7.4) containing 0.2% Nonidet P-40, 100 mM KCl, 5 mM
MgCl2, 0.5 mM EGTA, 1 mM DTT, and protease inhibitors.
Lysates were precleared with Protein G-Sepharose 4 beads and
immunoprecipitated with the anti-ASC antibody, and the
bead-bound proteins were immunoblotted with the appropri-
ate antibodies. All of the blots were representative images of at
least three independent experiments.
Quantification of mRNA Expression—To measure mRNA
expression of IL-1, Nlrp3, and Asc, a quantitative real-time
PCR assay was performed as described previously (22). Primers
were as follows: 5-GCCCATCCTCTGTGACTCAT-3 and
5-AGG CCA CAG GTA TTT TGT CG-3 (IL-1); 5-ATG
CTGCTTCGACATCTCCT-3 and 5-AACCAATGCGAG
ATC CTG AC-3 (Nlrp3); and 5-CTT GTC AGG GGA TGA
ACTCAAAA-3 and 5-GCCATACGACTCCAGATAGTA
GC-3 (Asc).
Assay of Inflammasome Activation and Assembly—To acti-
vate NLRP3 inflammasome signaling, BMDMs were primed
with LPS (0.25 g/ml) for 2–3 h, followed by treatment with
ATP (2.5 mM, 30 min), nigericin (5 M, 45 min), or alum (250
g/ml, 6 h). To determine inflammasome activity, the culture
supernatants were precipitated as described previously and
then immunoblotted with anti-caspase-1 or IL-1 antibody
(23). To determine the oligomerization of NLRP3, confocal
microscopy of NLRP3-GFP-expressing BMDMs was per-
formed using a confocal microscope (Zeiss LSM 700), as
described previously (22). To determine the oligomerization of
ASC, a chemical cross-linking assay was performed using dis-
uccinimidyl suberate as described previously (24). To visualize
ASC specklike oligomeric structure, an immunofluorescence
assaywas performed using anti-ASC antibody as described pre-
viously (22).
Assay of mROS, mtDNA Release, and Mitochondrial Mem-
brane Potential—To measure mROS production, cells were
resuspended in Hanks’ balanced salt solution after appropriate
treatments and stained with MitoSOX (2.5 M) at 37 °C for 20
min. The fluorescence of the cells was monitored and analyzed
by a flow cytometer (FACSVerse, BD Biosciences). To deter-
mine cytosolicmtDNA, cells were lysed, and cytosolic fractions
were prepared as described previously (11). Next, DNA was
isolated from the normalized cytosolic fraction, and the copy
number of DNA encoding cytochrome c oxidase I was deter-
mined via quantitative real-time PCR using the following prim-
ers: 5-GCC CCA GAT ATA GCA TTC CC-3 (forward) and
5-GTT CAT CCT GTT CCT GCT CC-3 (reverse). To deter-
mine mitochondrial potential-dependent damage, cells were
costained withMitoTracker Deep Red andMitoTracker Green
according to the manufacturer’s protocol. Cells were then ana-
lyzed by a flow cytometer.
Transmission ElectronMicroscopy—Cells were fixed with 2%
glutaraldehyde-paraformaldehyde in 0.1 M phosphate buffer,
pH 7.4, for 2 h. After washing, cells were postfixed with 1%
OsO4 in 0.1 M phosphate buffer for 2 h and dehydrated in
ascending gradual series (50–100%) of ethanol. Specimens
were embedded using a Poly/Bed 812 kit (Polysciences, Inc.).
70-nm thin sections were stained with uranyl acetate and lead
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citrate. Stained sections were then observed using a JEM-1011
(JEOL) transmission electron microscope.
Statistical Analysis—All values are expressed as the mean
and S.E. of individual samples. Data were analyzed using
Student’s t test. p values of0.05 were considered significant.
Results
Rotenone Induces NLRP3-dependent Caspase-1 Activation
withATPbutNotwithOtherNLRP3 Stimulators—Toprovide a
molecular insight into howmitochondrial dysfunction is impli-
cated in the activation of NLRP3 inflammasome signaling, we
first determined whether the mitochondrial impairment-in-
ducing chemicals rotenone and CCCP could function as a sig-
nal 2 stimulus for caspase-1 activation. Contrary to expecta-
tions, stimulation with rotenone or CCCP failed to trigger
caspase-1 activation in LPS-primed BMDMs (Fig. 1A). Of par-
ticular note was the fact that rotenone, but not CCCP, pro-
moted a robust caspase-1 processing with costimulation of
ATP inBMDMs (Fig. 1,A andB). Conversely, CCCP attenuated
LPS/ATP-triggered caspase-1 activation (Fig. 1C). Like LPS/
ATP stimulation, rotenone/ATP stimulation caused an
NLRP3- andASC-dependent caspase-1 activation (Fig. 1,D and
FIGURE 1.Rotenone promotes NLRP3 inflammasome activation onlywith ATP costimulation. A, mouse BMDMswere untreated (Unt) or treatedwith
LPS (0.25 g/ml) for 3 h, followed by treatment with CCCP (40 M) or rotenone (Rot) (10 M) for 2 h, or were treated with CCCP or rotenone for 2 h,
followed by treatment with ATP (2.5 mM, 30 min), as indicated. B, mouse BMDMs were treated with CCCP or rotenone (1–20 M) for 2 h, followed by
treatment with ATP. C, mouse BMDMs were treated with LPS in the presence of CCCP or rotenone (1–10 M) for 2 h, followed by ATP treatment. D and
E, primary WT or Nlrp3/ BMDMs (D), or immortalized WT, Nlrp3/, or Asc/ BMDMs (E) were untreated or treated with LPS or rotenone (10 M) for
3 h, followed by treatment with ATP. F, mouse BMDMs were treated with LPS or rotenone (5 M) for 3 h, followed by ATP, nigericin (Nig), or alum
treatment, as indicated under “Experimental Procedures.” A–F, culture supernatants (Sup) or cellular lysates (Lys) were immunoblotted with the
indicated antibodies.
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E), suggesting that rotenone appears to function as a signal 1
priming stimulus for NLRP3 inflammasome activation. How-
ever, rotenone had a negligible effect on transcriptional induc-
tion of pro-IL-1 and thus inducedmuch lower IL-1 secretion
with ATP costimulation as compared with LPS (Fig. 1D). These
results indicate that the impairment of mitochondrial complex
I by rotenone may facilitate the activation of NLRP3 inflam-
masome in a transcription-independent manner.
Next, we tested the NLRP3-priming role played by rotenone
with costimulation of other well known NLRP3 stimuli.
Intriguingly, rotenone did not promote any caspase-1 activa-
tion upon costimulation with nigericin or alum (Fig. 1F). This
unexpected finding indicates that rotenone-induced mito-
chondrial dysfunction may mediate selective NLRP3 inflam-
masome activation exclusively with costimulation of ATP, but
not of other conventional activators.
Rotenone Promotes the Assembly of NLRP3 Inflammasome
Only in the Presence of ATP—To examine whether rotenone-
triggered mitochondrial dysfunction mediates the assembly of
NLRP3 inflammasome, we determined the formation of speck-
like aggregates of NLRP3 or ASC and examined the association
between NLRP3 and ASC. Both molecular assemblies are
essential prerequisite steps for the activation of NLRP3 inflam-
masome (25, 26). Consistent with the aforementioned results,
rotenone with ATP costimulation, but not with nigericin
costimulation, induced a robust formation of NLRP3 specklike
aggregates (Fig. 2, A and B). Rotenone also promoted substan-
tial association of NLRP3 with ASC exclusively in the presence
of ATP costimulation and not in the presence of nigericin (Fig.
2C). Supporting these data, rotenone/ATP costimulation, but
not rotenone/nigericin, triggered a robustASColigomerization
and ASC speck formation (Fig. 2,D and E). These observations
FIGURE 2. Rotenone promotes the formation of NLRP3 inflammasome assembly only with ATP costimulation. A and B, immortalized NLRP3-GFP-
expressing BMDMs were treated with rotenone (Rot) (5 M) or LPS (0.25 g/ml) for 3 h, followed by ATP (2.5 mM, 30 min) or nigericin (Nig) (5 M, 40 min)
treatment. Specklike aggregates of NLRP3 were observed by confocal microscope (A, scale bars, 10 m), and the relative percentages of NLRP3 speck-
containing cells were plotted (B; n 3). C, mouse BMDMswere treatedwith rotenone (5M) or LPS (0.5g/ml) for 2 h, followed by treatment with ATP (2mM)
or nigericin (5 M) for 30 min. Soluble lysates were immunoprecipitated (IP) with anti-ASC antibody, and the immunoprecipitates or soluble lysates were
immunoblotted, as indicated.D, mouse BMDMswere treatedwith LPS or rotenone (5M) for 3 h, followed by ATP or nigericin treatment. ASC oligomerization
was assayed as described under “Experimental Procedures.” E, mouse BMDMswere treatedwith rotenone or LPS, followed byATP or nigericin treatment. Cells
were stained with anti-ASC antibody and observed by confocal microscope. Scale bars, 20 m. Error bars, S.E.
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also support the contention that rotenone-mediatedmitochon-
drial dysfunctionmay selectively prime the assembly of NLRP3
inflammasome only in the context of specific costimulation,
such as ATP costimulation.
Rotenone/ATPStimulationPromotes theTranscription-inde-
pendent Caspase-1 Activation—To examine whether rote-
none-mediated priming of NLRP3 inflammasome activation
involves the transcription of NLRP3 or ASC, we measured
mRNA levels of NLRP3 and ASC. Neither rotenone nor rote-
none/ATP stimulation induced a significant increase in the
transcription level of NLRP3, ASC, or pro-IL-1 (Fig. 3, A–C).
To further verify whether rotenone/ATP stimulation could
activate NLRP3 inflammasome in a transcription-independent
manner, we performed a similar experiment in the reconsti-
tuted NLRP3-expressing macrophages (N1–8), which stably
express NLRP3 irrespective of Toll-like receptor signaling, as
reportedly previously (6). As observed in primary or immortal-
ized BMDMs, rotenone induced a robust caspase-1 activation
only with ATP costimulation (Fig. 3D).
Rotenone/ATP Stimulation Induces High-grade mROS Pro-
duction and mtDNA Release into the Cytosol—Previous studies
have demonstrated that inhibition of the mitochondrial elec-
tron transport chain by rotenone or antimycin A leads to the
generation of mROS (10, 17). To test whether rotenone-medi-
ated mROS production is responsible for NLRP3 inflam-
masome activation upon rotenone/ATP stimulation, we deter-
mined the intracellular level of mROS usingMitoSOX staining.
Rotenone treatment substantially increased mROS-producing
macrophages, but the level of mROS production was low in
mostMitoSOX-positive cells (Fig. 4,A and B). Indeed, the pop-
ulation of high-grade mROS-producing macrophages was only
slightly increased by rotenone (5.58%; Fig. 4A). Conversely,
ATP stimulation caused a considerable increase (25–27%) in
strong mROS-producing cells (Fig. 4, A and B). Considering
that stimulation with ATP alone did not induce caspase-1 acti-
vation (Figs. 1A and 3D), ATP-induced high-grade mROS pro-
duction is not sufficient for caspase-1 activation. Intriguingly,
rotenone/ATP stimulation caused a remarkable increase in
strong mROS-positive cells, whereas rotenone/nigericin treat-
ment showed no such increase (Fig. 4, A and B). This finding
suggests that highly elevated strong mROS production by rote-
none/ATP may contribute to caspase-1 activation. Similarly,
rotenone/ATP stimulation promoted a marked release of
mtDNA into the cytosol, whereas rotenone or rotenone/nige-
ricin induced much less cytosolic release of mtDNA (Fig. 4C).
These data collectively indicate that rotenone/ATP stimula-
tion, but not rotenone/nigericin stimulation, mediates the pro-
duction of strong mROS and the cytosolic release of mtDNA,
possibly contributing to NLRP3 inflammasome activation.
Rotenone/ATP-induced Generation of Mitochondrial Toxic
Products Differentially Contributes to NLRP3 Inflammasome
Activation—A recent study has proposed that active caspase-1
induces mitochondrial damage as an effector function of
caspase-1 (27). In order to examine whether the increased
strong mROS production and mtDNA release are conse-
quences of augmented caspase-1 activation by rotenone/ATP
stimulation, we assessed the rotenone/ATP-triggered genera-
tion ofmitochondrial toxic products in inflammasome activity-
deficient Asc/ BMDMs. As observed in wild-type BMDMs,
rotenone/ATP stimulation induced amarked increase in strong
mROS production in Asc/ BMDMs (Fig. 5A). Supporting
these data, pan-caspase inhibitor Z-VAD did not impair rote-
none/ATP-triggered strong mROS production (Fig. 5B), dem-
onstrating that the elevated strong mROS production is not
caused by enhanced caspase-1 activation. Furthermore, the
antioxidant NAC efficiently abolished rotenone/ATP-triggered
caspase-1 activation (Fig. 5C). These results indicate that high-
grade mROS production is crucial for rotenone/ATP-mediated
caspase-1 activation. By contrast, CCCP did not induce the pro-
duction of high-grade mROS (Fig. 5D). This might partly explain
the failureofCCCP toactivate caspase-1 (Fig. 1,A andB), contrary
to the previous report (10).
UnlikemROS production, mtDNA release by rotenone/ATP
was significantly impaired in Asc/ BMDMs (Fig. 5E). More-
over, the inhibition of caspase-1 activation by Z-VAD similarly
decreased the rotenone/ATP-induced mtDNA release into the
cytosol (Fig. 5F). These findings suggest that some indications
of mitochondrial damage, such as mtDNA release, may reflect
potentiated caspase-1 activation by rotenone/ATP stimulation.
Furthermore, cyclosporin A was previously shown to inhibit
NLRP3-mediated caspase-1 activation by blocking mitochon-
drial membrane permeability transition (MPT) pores (13). We
therefore examined whether the MPT is implicated in rote-
none/ATP-mediated caspase-1 activation. Cyclosporin A
largely abolished LPS/ATP-mediated caspase-1 activation but
FIGURE 3. Rotenone/ATP stimulation causes transcription-independent
caspase-1 activation. A–C, mouse BMDMs were treated with rotenone (Rot)
or LPS, followed by ATP treatment, as indicated. Then mRNA levels of Nlrp3,
Asc, or IL-1weredeterminedbyquantitative real-timePCR.Asterisks indicate
significant difference as compared with untreated (Unt) samples (*, p 0.05,
n3 (A); **,p0.01,n3 (C)).D, immortalizedNLRP3-reconstitutedBMDMs
(N1–8) were treated with rotenone or LPS, followed by ATP treatment. Cul-
ture supernatants (Sup) or cellular lysates (Lys) were immunoblottedwith the
indicated antibodies. Error bars, S.E.
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not rotenone/ATP-induced caspase-1 activation (Fig. 5G). This
finding indicates that rotenone/ATP-mediated caspase-1 acti-
vation is independent of MPT.
mROS Production Is Not Sufficient to Promote NLRP3
Inflammasome Activation—To provide more insight into the
rotenone/ATP-mediated caspase-1 activation, we observed
mitochondrial morphology by transmission electron micros-
copy. Rotenone/ATP costimulation as well as treatment with
ATP alone induced a disruption of mitochondrial cristae, lead-
ing to the formation of vesicular matrix compartments (Fig.
6A). The disruption of mitochondrial crista organization was
inhibited byMito-TEMPO, a specific mROS scavenger, but not
FIGURE 4.Rotenone/ATP stimulation causes strongmROSproduction andmtDNA release into the cytosol.A and B, mouse BMDMswere untreated (Unt)
or treatedwith rotenone (Rot) (5M) or LPS for 2 h, followedby treatmentwithATP (2.5mM, 20min) or nigericin (Nig) (5M, 30min), as indicated. The cellswere
then stained with MitoSOX and analyzed by a flow cytometer. Four or three independent experiments were performed, and total mROS- or strong mROS-
generating cells are plotted in B. Asterisks indicate significant differences as compared with ATP-treated samples (n 4; *, p 0.05; **, p 0.005). C, mouse
BMDMs were treated with rotenone (5 M, 3 h), followed by treatment with ATP (2.5 mM, 20 min) or nigericin (5 M, 30 min). Cytosolic mtDNA was quantified
as described under “Experimental Procedures.” Asterisks indicate significant differences as compared with rotenone-treated samples (n 9; **, p 0.0005).
Error bars, S.E.
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by Z-VAD. This finding proposed that high-grade mROS pro-
duction by rotenone/ATP or ATP is critical for the deranged
cristae. However, mROS-mediated mitochondrial dysfunction
is not sufficient for caspase-1 activation, because ATP failed to
activate caspase-1.
To verify whether mROS production could mediate NLRP3
inflammasome activation, BMDMs were treated with the ROS
generator menadione. As reported previously (28), menadione
promoted considerable mROS production (Fig. 6B). Of note,
menadione/ATP induced robust high-grade mROS produc-
tion, similar to rotenone/ATP (Fig. 6B). However, menadione
stimulation did not cause caspase-1 activation in the presence
of LPS or ATP (Fig. 6C), indicating that other crucial factors in
addition to mROS are required for the activation of NLRP3
inflammasome upon mitochondrial dysfunction.
Mitochondrial Hyperpolarization Is Important in Rotenone/
ATP-mediated Caspase-1 Activation—Mitochondrial mem-
brane potential is not only essential for producing cellular
energy but is also required for regulating innate immune
responses (20, 29). We therefore examined whether alterations
in mitochondrial membrane potential are implicated in the
activation of NLRP3 inflammasome upon rotenone/ATP stim-
FIGURE 5. Inflammasome activation is differentially responsible for rotenone/ATP-inducedmROS production andmtDNA release. A and B, immortal-
ized WT or Asc/ BMDMs (A) or primary WT BMDMs (B) were treated with rotenone (Rot) (5 M, 2 h) in the presence of Z-VAD-fmk (20 M) (B), followed by
treatment with ATP (2.5 mM, 15 min (A) or 20 min (B)). C, mouse BMDMs were treated with rotenone (5 M, 3 h) in the presence of NAC (20 mM), followed by
treatment with ATP. D, mouse BMDMs were treated with rotenone, followed by treatment with ATP, or treated with CCCP (20 M, 2 h). A, B, and D, mROS
production was assayed usingMitoSOX staining as in Fig. 4. E and F, immortalizedWT or Asc/ BMDMs (E) or primary BMDMs (F) were treated with rotenone
in the presence of Z-VAD-fmk (20M) (F), followed by treatment with ATP. Cytosolic mtDNAwas assayed, and asterisks indicate significant differences (n 3;
*, p 0.05; **, p 0.0001).G, mouse BMDMswere treatedwith rotenone or LPS (3 h) in the presence of cyclosporin A (CsA; 10 or 20M), followed by treatment
with ATP. C and G, culture supernatants or soluble lysates were immunoblotted. Unt, untreated. Error bars, S.E.
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ulation. Rotenone treatment exhibited a slight increase inmito-
chondrial membrane potential, as determined by costaining of
Mitotracker Deep Red andMitotracker Green (7.3%) (Fig. 7A).
The fluorescence intensity ofMitotracker Deep Red represents
membrane potential. Of greater interest, ATP stimulation in
the presence of rotenone pretreatment caused a dramatic
increase in the cell population containing hyperpolarizedmito-
chondria (Rot  ATP; Fig. 7A), whereas nigericin in the pres-
ence of rotenone exhibited a negligible effect. In addition, the
population of cells containing damaged or depolarized mito-
chondria (bottom right box) was also increased only in rote-
none/ATP-stimulated BMDMs (Fig. 7A). These results clearly
indicate that rotenone/ATP stimulation causes a marked alter-
ation inmitochondrial membrane potential that maymodulate
the activation of NLRP3 inflammasome.
Interestingly, the cells containing depolarized mitochondria
upon rotenone/ATP stimulation showed a clear reduction in
cell size, as determined by forward scatter signature, whereas
the cells containing hyperpolarized mitochondria exhibited a
slight increase in cell size and complexity as compared with
untreated cells (Fig. 7B). Furthermore, the population of cells
containing depolarized mitochondria increased along with
ATP treatment time, whereas that of hyperpolarized mito-
chondria-containing cells decreased (Fig. 7C). Thus,mitochon-
drial depolarization may reflect mitochondrial damage rather
than acting as the causative factor in NLRP3 inflammasome
activation.
Indeed, a recent study has shown that the LPS/ATP-medi-
ated increase in mitochondrial damage is dependent on
caspase-1 activity (27). To determine whether the aforemen-
tioned hyperpolarization or depolarization of mitochondrial
membrane potential is a consequence of inflammasome activa-
tion, we examined the rotenone/ATP-induced alteration of
mitochondrial membrane potential in ASC-deficient macro-
phages. Consequently, mitochondrial depolarization as well as
hyperpolarization were also evident in Asc/ BMDMs upon
rotenone/ATP stimulation, as in wild-type BMDMs (Fig. 8, A
and B). These data suggest that rotenone/ATP-induced altera-
tions in mitochondrial membrane potential did not result from
caspase-1/inflammasome activation. Furthermore, depolarized
FIGURE 6. Strong mROS production impairs mitochondrial structure but is not sufficient to activate NLRP3 inflammasome. A, transmission electron
microscopy images of mouse BMDMs treated with rotenone (Rot) (5M, 3 h) in the presence of Z-VAD-fmk (20M) or Mito-TEMPO (MT) (250M), followed by
ATP treatments (2.5mM, 10min), as indicated. Scale bars, 1m.B,mouseBMDMswere treatedwithmenadione (MD) (20M)or rotenone (5M) for 2h, followed
by ATP treatments (2.5 mM, 15 min). Cells were then stained with MitoSOX and analyzed by a flow cytometer. C, mouse BMDMs were treated with LPS (0.25
g/ml, 3 h), followed bymenadione (2 h) or ATP treatment, or treated with menadione (2 h), followed by ATP treatments, as indicated. Cultural supernatants
or cellular lysates were immunoblotted with anti-caspase-1 antibody. Unt, untreated.
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mitochondria-containing cells in Asc/ macrophages also
exhibited reduced cell size (Fig. 8C), demonstrating that rote-
none/ATP-induced mitochondrial damage is inflammasome
activity-independent. More importantly, mitochondrial depo-
larization by CCCP markedly abolished rotenone/ATP-medi-
ated caspase-1 activation (Fig. 8D). Therefore, we concluded
that mitochondrial hyperpolarization is critical for rotenone/
ATP-mediated triggering of NLRP3 inflammasome activation,
but depolarization is an indication of mitochondrial damage.
As described above, a well knownmROS generator, menadi-
one, failed to activateNLRP3 inflammasome activation. Indeed,
menadione even in the presence of ATP did not promote sig-
nificant mitochondrial hyperpolarization (Fig. 8E). These
observations also indicate that mitochondrial hyperpolariza-
tion is essential for NLRP3 inflammasome activation upon
mitochondrial dysfunction.
Potassium Efflux and Deubiquitination of NLRP3 Are Impli-
cated in Rotenone/ATP-mediated Caspase-1 Activation—
Extracellular ATP stimulates the efflux of intracellular potas-
sium through its binding to the P2X7 receptor (30). Potassium
efflux is a crucial cellular event for NLRP3 inflammasome
assembly and activation (19), although its underlying mecha-
nism remains poorly understood. To examine whether potas-
sium efflux is associated with the caspase-1 activation by rote-
none/ATP stimulation, cellswere treatedwith glibenclamide or
a high concentration of extracellular KCl to block potassium
FIGURE 7.Rotenone/ATP stimulation causes alterations inmitochondrialmembranepotential.A and B, mouse BMDMswere treatedwith rotenone (Rot),
followed by treatment with ATP (2.5mM, 20min) or nigericin (Nig) (5M, 30min). Cells were costainedwithMitoTracker Deep Red andMitoTracker Green and
analyzed by a flow cytometer. Cells at the top left and the bottom right represent mitochondrial hyperpolarization and depolarization, respectively. Cells were
also analyzed by forward scatter (FSC) and side scatter (SSC) in B. C, mouse BMDMswere treatedwith rotenone, followed by ATP (5, 15, or 30min), as indicated.
Cells were stained and analyzed by a flow cytometer as in A. Unt, untreated.
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efflux. Consequently, the inhibition of potassium efflux by glib-
enclamide or extracellular KCl largely abolished rotenone/
ATP-mediated caspase-1 activation (Fig. 9, A and B), demon-
strating that potassium efflux is potentially involved in
mitochondrial dysfunction-mediated caspase-1 activation. By
contrast, the inhibition of potassium efflux resulted in a negli-
gible or slight reduction in high-grade mROS production and
mitochondrial hyperpolarization induced by rotenone/ATP
stimulation (Fig. 9C). These findings suggest that potassium
effluxmight be the downstreamevent ofmROSproduction and
hyperpolarization.
Although it is still unclear howNLRP3 is activated upon clas-
sical priming and signal 2 stimulations, several mechanisms
have recently been proposed, including ERK phosphorylation
and deubiquitination ofNLRP3. For instance, LPS priming pro-
motes the activation of ERK signaling, which in turn is required
for NLRP3 activation (8). In addition, deubiquitination of
NLRP3 triggered either by LPS priming or ATP stimulation is
also required to activate NLRP3 (6, 7). To examine whether
these molecular events are crucial for rotenone/ATP-mediated
caspase-1 activation, we used well known selective inhibitors,
such as U0126, to inhibit MEK1/2-dependent ERK phosphory-
lation, and we used PR619 to inhibit general deubiquitinating
enzymes. Inhibition of ERK signaling byU0126 attenuatedLPS/
ATP-mediated caspase-1 activation but did not impair rote-
none/ATP-promoted caspase-1 activation (Fig. 9D). However,
deubiquitinase inhibitor PR619 completely abolished rote-
none/ATP-triggered caspase-1 activation (Fig. 9D). This obser-
vation suggests that rotenone/ATP stimulation may mediate
deubiquitination of NLRP3 for its activation.
Discussion
Mitochondrial dysfunctions caused by a genetic mutation or
defective function of mitochondrial proteins have been impli-
cated in numerous neurodegenerative or metabolic diseases
(14). Many therapeutic drugs are also able to inducemitochon-
FIGURE 8. Rotenone/ATP-mediated alterations in mitochondrial membrane potential are independent of inflammasome activation. A–C, immortal-
ized WT or ASC-deficient BMDMs were treated with rotenone (Rot), followed by treatment with ATP (2.5 mM, 15 min). Cells were costained with MitoTracker
Deep Red and MitoTracker Green and analyzed by a flow cytometer. Relative cell populations in the top left (Hyper) and the bottom right panels (De) were
plotted as in B (n 4). Cells were also analyzed by forward scatter (FSC) and side scatter (SSC) as in Fig. 7C.D, mouse BMDMswere treatedwith rotenone in the
presence of CCCP (5M), followed by treatment with ATP. Culture supernatants (top) or soluble lysates (bottom) were immunoblotted. E, mouse BMDMswere
treated with menadione (MD) (20 M, 2 h) in the presence of LPS, as indicated, or rotenone (5M, 2 h), followed by ATP treatments. Cells were costained with
MitoTracker Deep Red and MitoTracker Green and analyzed by a flow cytometer. Unt, untreated. Error bars, S.E.
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drial dysfunction as an off-target effect, possibly causing or
aggravating the disease state. In particular, dysfunction ofmito-
chondrial electron transport complex I has been regarded as a
main contributor to Leber hereditary optic neuropathy, Leigh
syndrome, and Parkinson disease (14, 15, 31). Supporting these
findings, the inhibition ofmitochondrial complex I by rotenone
or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine has been
used to induce Parkinson disease in animal models (18, 32).
Given the important role played by abnormal mitochondrial
ETC in degenerative diseases, our data present further evidence
in support of the argument that the impairment of mitochon-
drial complex I may promote NLRP3 inflammasome activation
in the presence of extracellular ATP, which is commonly
derived from adjacent injured cells.
Despite growing interest in mitochondrial regulation of the
inflammasome pathway, the limited earlier studies were con-
troversial in terms of the effect of mitochondrial dysfunction-
inducing chemicals, such as rotenone or CCCP, on NLRP3
inflammasome activation (10, 13, 19, 20). Our results clearly
indicate that rotenone, but not CCCP, may trigger NLRP3
inflammasome priming only with ATP costimulation in
BMDMs. This finding emphasizes that not all mitochondrial-
damaging stimulations contribute to the activation of the
NLRP3 inflammasome.
Previous studies focused on mROS production by rotenone-
mediated complex I inhibition in order to explain the toxic
effect of rotenone (16, 17). Indeed, rotenone treatment caused
low-grade mROS production (Fig. 4A), but the latter was not
sufficient to activate the NLRP3 inflammasome (Figs. 1A and
3D). Of particular interest, high-grade mROS production was
remarkably elevated in rotenone/ATP stimulation but not in
rotenone/nigericin, LPS/nigericin, or CCCP stimulation. Fur-
ther supporting these findings, the antioxidant NAC abolished
rotenone/ATP-triggered caspase-1 activation. These data sug-
gest that aberrant production of high-grade mROS, but not
weak mROS, is critical for rotenone/ATP-mediated NLRP3
FIGURE 9. Potassium efflux and NLRP3 deubiquitination are implicated in rotenone/ATP-mediated caspase-1 activation. A, mouse BMDMs were
pretreated with Z-VAD (20 M) or glibenclamide (gliben) (50 M) for 30 min and then treated with rotenone (Rot) (5 M, 3 h), followed by treatment with ATP.
B, mouse BMDMswere treatedwith rotenone in the presence of NAC (20mM), followed by treatmentwith KCl (60 or 100mM, 15min before ATP) andATP (final
30 min) treatment, as indicated. C, mouse BMDMs were treated with rotenone, followed by treatment with KCl (100mM, 15min before ATP) and ATP (final 20
min). Cells were analyzed by a flow cytometer after staining with MitoSOX (left) or costaining with MitoTracker Deep Red and MitoTracker Green (right). D,
mouse BMDMswere treatedwith rotenone or LPS in the presence of U0126 (10M) or PR619 (5M), followedbyATP (30-min) treatment, as indicated.A, B, and
D, culture supernatants (Sup) or soluble lysates (Lys) were immunoblotted. Unt, untreated.
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inflammasome activation. However, neither ATP nor menadi-
one/ATP stimulation activates NLRP3 inflammasome despite
their ability to produce high-grade mROS. In addition, ATP
clearly disrupted mitochondrial cristae structure. These data
suggest that high-grademROS induces amitochondrial impair-
ment but is not sufficient to trigger NLRP3 inflammasome
activation.
Notably, rotenone/ATP stimulation caused alterations in
mitochondrial membrane potential. The importance of mito-
chondrial membrane potential in the NLRP3 inflammasome
has not been fully explored. Several previous studies have pro-
posed that CCCP or classical NLRP3-activating stimulations
cause mitochondrial depolarization, which may lead to NLRP3
inflammasome activation (10, 12). However, our data indicate
that rotenone/ATP-mediated mitochondrial depolarization
may be the indication of mitochondrial damage in an
inflammasome-independent manner rather than an NLRP3-
activating factor. Supporting this hypothesis, mitochondrial
depolarization by CCCP completely abolished rotenone/ATP-
mediated caspase-1 activation.
Instead, our data suggest that mitochondrial hyperpolariza-
tion by rotenone/ATP is potentially implicated in NLRP3
inflammasome activation. The failure of ATP or menadione/
ATP to activate caspase-1may stem from a defect in promoting
the hyperpolarization ofmitochondria despite their robust pro-
duction of high-grademROS. Therefore, we propose thatmito-
chondrial hyperpolarization is needed to activate NLRP3
inflammasome activation upon mitochondrial dysfunction. In
accordance with our results, previous studies have proposed
that intact mitochondrial membrane potential is required for
type 1 interferon production and NLRP3 inflammasome acti-
vation in response to RNA virus infection (20, 29). Further-
more, mitochondrial hyperpolarization triggered by the defi-
ciency of UCP-2 (uncoupling protein-2) or oxygen-glucose
deprivation exacerbates neuronal damage (33, 34). The molec-
ular mechanism by which mitochondrial hyperpolarization
may trigger NLRP3 activation remains poorly understood. Fur-
ther studies will therefore be needed to elucidate the molecular
details involved in this phenomenon.
A previous study has shown thatmROSmediates the deubiq-
uitination of NLRP3, which is an important priming step for
NLRP3 activation (6). Given that deubiquitination is also impli-
cated in rotenone/ATP-mediated caspase-1 activation (Fig.
9D), high-grade mROS may promote NLRP3 inflammasome
activation through its deubiquitinating potential in our exper-
imental system. By contrast, mtDNA release appears to result
from inflammasome activation upon rotenone/ATP stimula-
tion. This result also emphasizes the fact that indications of
mitochondrial damage are not only a priming signal for NLRP3
inflammasome activation but also the consequence of
caspase-1 activation.
In conclusion, the impairment of mitochondrial ETC
complex I by rotenone increases the sensitivity of the assem-
bly and activation of NLRP3 inflammasome in response to
extracellular ATP commonly originating from injured cells
or tissues. Robust high-grade mROS production as well as
mitochondrial hyperpolarization might mediate the selec-
tive activation of NLRP3 inflammasome. Our results thus
suggest that a specific inhibition of these mitochondrial
alterations may be used to alleviate aberrant NLRP3 inflam-
masome toxicity.
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